QPPV.COM KNOWLEDGE ASSESSMENT

Losartan: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Losartan: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which information set would be most useful when assessing a report of pregnancy exposure to losartan?
Question 2 of 10 A patient with chronic kidney disease has a creatinine increase soon after starting losartan. What is the most appropriate pharmacovigilance interpretation?
Question 3 of 10 What is the most appropriate conclusion from comparative losartan studies in heart failure described in the article?
Question 4 of 10 How should the US label's qualification concerning the LIFE stroke-risk finding in Black patients be interpreted?
Question 5 of 10 What did the EMA Article 30 referral concerning Cozaar principally illustrate?
Question 6 of 10 Which distinction is most important when evaluating a suspected pharmacological adverse reaction alongside a possible nitrosamine quality defect?
Question 7 of 10 An inspector reviews a marketing authorisation holder's handling of several suspected losartan-related renal events. Which evidence would best demonstrate an effective and traceable system?
Question 8 of 10 A team is investigating a complaint potentially related to a nitrosamine-contaminated losartan lot. Which evidence trail is most appropriate for the quality investigation?
Question 9 of 10 A patient taking losartan develops hyperkalaemia while also using a potassium-containing salt substitute and a potassium-sparing medicine. Which assessment is best?
Question 10 of 10 Which statement best explains why losartan's active metabolite and hepatic metabolism may matter in a clinical assessment?

Select an answer to continue.

QPPV.com